Over the course of 72 weeks, people on tirzepatide lost an average of 20.2% of their body weight, or about 50 pounds. Those on semaglutide lost 13.7%, around 33 pounds.

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the SURMOUNT-5 trial. As Healio previously ...

The tirzepatide group lost 21.4% of their body weight from baseline to 1 year and the semaglutide group achieved a 9.1% weight reduction in that same period (P for treatment difference < .0001).

Those taking semaglutide lost 9.1% of their body weight on average over 12 months, which equates to 19.2lb (8.7kg). Their BMI decreased by 3kg/m 2, on average over 12 months.

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference. Fox News Media; ...

Notably, 31.6% of patients receiving tirzepatide achieved at least 25% body weight loss (key secondary endpoint) compared with 16.1% of those taking semaglutide.

In this study, scientists have explored the effects of VLCD and Semaglutide, both individually and in combination, on body weight, body composition, and metabolic outcomes in type 2 diabetes patients.

Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which are sometimes taken off-label for weight loss.

Participants with obesity (a body-mass index [BMI; the weight in kilograms divided by the square of the height in meters] of ≥30) and a clinical and radiologic diagnosis of moderate knee ...

If you use insulin, you may inject semaglutide into the same area of your body as insulin, but you should not inject one right next to the other. Semaglutide is not a replacement for insulin.

Over the course of 72 weeks, people on tirzepatide lost an average of 20.2% of their body weight, or about 50 pounds. Those on semaglutide lost 13.7%, around 33 pounds.